List of Revance Therapeutics, Inc. patents

Patents where

Current Assignee

Name

‌

Revance Therapeutics, Inc.

Name	Description	Patent Applicant	Current Assignee	Patent Jurisdiction	Patent Number	Date of Patent
‌ US Patent 10080786 Methods for treating pain by topical application and transdermal delivery of botulinum toxin	Patent 10080786 was granted and assigned to Revance Therapeutics, Inc. on September, 2018 by the United States Patent and Trademark Office.	‌ Revance Therapeutics, Inc.	‌ Revance Therapeutics, Inc.	United States Patent and Trademark Office	10080786	September 25, 2018
‌ US Patent 8398997 Compositions and methods for topical application and transdermal delivery of botulinum toxins	Patent 8398997 was granted and assigned to Revance Therapeutics, Inc. on March, 2013 by the United States Patent and Trademark Office.		‌ Revance Therapeutics, Inc.	United States Patent and Trademark Office	8398997	March 19, 2013
‌ US Patent 8404249 Compositions and methods for topical application and transdermal delivery of botulinum toxins	Patent 8404249 was granted and assigned to Revance Therapeutics, Inc. on March, 2013 by the United States Patent and Trademark Office.		‌ Revance Therapeutics, Inc.	United States Patent and Trademark Office	8404249	March 26, 2013
‌ US Patent 11484580 Topical ocular preparation of botulinum toxin for use in ocular surface disease	Patent 11484580 was granted and assigned to Revance Therapeutics, Inc. on November, 2022 by the United States Patent and Trademark Office.	‌ Revance Therapeutics, Inc.	‌ Revance Therapeutics, Inc.	United States Patent and Trademark Office	11484580	November 1, 2022
‌ US Patent 9314416 Compositions and methods for topical application and transdermal delivery of botulinum toxins	Patent 9314416 was granted and assigned to Revance Therapeutics, Inc. on April, 2016 by the United States Patent and Trademark Office.		‌ Revance Therapeutics, Inc.	United States Patent and Trademark Office	9314416	April 19, 2016
‌ US Patent 10201594 Compositions and methods for safe treatment of rhinitis	Patent 10201594 was granted and assigned to Revance Therapeutics, Inc. on February, 2019 by the United States Patent and Trademark Office.	‌ Revance Therapeutics, Inc.	‌ Revance Therapeutics, Inc.	United States Patent and Trademark Office	10201594	February 12, 2019
‌ US Patent 9180081 Compositions and methods for topical application and transdermal delivery of botulinum toxins	Patent 9180081 was granted and assigned to Revance Therapeutics, Inc. on November, 2015 by the United States Patent and Trademark Office.		‌ Revance Therapeutics, Inc.	United States Patent and Trademark Office	9180081	November 10, 2015
‌ US Patent 11471708 Injectable botulinum toxin formulations		‌ Revance Therapeutics, Inc.	‌ Revance Therapeutics, Inc.	United States Patent and Trademark Office	11471708	October 18, 2022
‌ US Patent 9956435 Injectable botulinum toxin formulations	Patent 9956435 was granted and assigned to Revance Therapeutics, Inc. on May, 2018 by the United States Patent and Trademark Office.		‌ Revance Therapeutics, Inc.	United States Patent and Trademark Office	9956435	May 1, 2018
‌ US Patent 10111939 Albumin-free botulinum toxin formulations	Patent 10111939 was granted and assigned to Revance Therapeutics, Inc. on October, 2018 by the United States Patent and Trademark Office.	‌ Revance Therapeutics, Inc.	‌ Revance Therapeutics, Inc.	United States Patent and Trademark Office	10111939	October 30, 2018
‌ US Patent 9469849 Methods and systems for purifying non-complexed botulinum neurotoxin	Patent 9469849 was granted and assigned to Revance Therapeutics, Inc. on October, 2016 by the United States Patent and Trademark Office.	‌ Revance Therapeutics, Inc.	‌ Revance Therapeutics, Inc.	United States Patent and Trademark Office	9469849	October 18, 2016
‌ US Patent 7807780 Multi-component biological transport systems	Patent 7807780 was granted and assigned to Revance Therapeutics, Inc. on October, 2010 by the United States Patent and Trademark Office.		‌ Revance Therapeutics, Inc.	United States Patent and Trademark Office	7807780	October 5, 2010
‌ US Patent 9340587 Albumin-free botulinum toxin formulations	Patent 9340587 was granted and assigned to Revance Therapeutics, Inc. on May, 2016 by the United States Patent and Trademark Office.		‌ Revance Therapeutics, Inc.	United States Patent and Trademark Office	9340587	May 17, 2016
‌ US Patent 11351232 Albumin-free botulinum toxin formulations		‌ Revance Therapeutics, Inc.	‌ Revance Therapeutics, Inc.	United States Patent and Trademark Office	11351232	June 7, 2022
‌ US Patent 11466262 Methods and systems for purifying non-complexed	Patent 11466262 was granted and assigned to Revance Therapeutics, Inc. on October, 2022 by the United States Patent and Trademark Office.	‌ Revance Therapeutics, Inc.	‌ Revance Therapeutics, Inc.	United States Patent and Trademark Office	11466262	October 11, 2022
‌ US Patent 8962548 Multi-component biological transport systems	Patent 8962548 was granted and assigned to Revance Therapeutics, Inc. on February, 2015 by the United States Patent and Trademark Office.		‌ Revance Therapeutics, Inc.	United States Patent and Trademark Office	8962548	February 24, 2015
‌ US Patent 9901627 Topical ocular preparation of botulinum toxin for use in ocular surface disease	Patent 9901627 was granted and assigned to Revance Therapeutics, Inc. on February, 2018 by the United States Patent and Trademark Office.	‌ Revance Therapeutics, Inc.	‌ Revance Therapeutics, Inc.	United States Patent and Trademark Office	9901627	February 27, 2018
‌ US Patent 9950042 Extended length botulinum toxin formulation for human or mammalian use	Patent 9950042 was granted and assigned to Revance Therapeutics, Inc. on April, 2018 by the United States Patent and Trademark Office.	‌ Revance Therapeutics, Inc.	‌ Revance Therapeutics, Inc.	United States Patent and Trademark Office	9950042	April 24, 2018
‌ US Patent 9211248 Compositions and methods for topical application and transdermal delivery of botulinum toxins	Patent 9211248 was granted and assigned to Revance Therapeutics, Inc. on December, 2015 by the United States Patent and Trademark Office.	‌ Revance Therapeutics, Inc.	‌ Revance Therapeutics, Inc.	United States Patent and Trademark Office	9211248	December 15, 2015
‌ US Patent 8623811 Antimicrobial peptide, compositions, and methods of use	Patent 8623811 was granted and assigned to Revance Therapeutics, Inc. on January, 2014 by the United States Patent and Trademark Office.		‌ Revance Therapeutics, Inc.	United States Patent and Trademark Office	8623811	January 7, 2014
‌ US Patent 8815954 Arginine heteromers for topical administration	Patent 8815954 was granted and assigned to Revance Therapeutics, Inc. on August, 2014 by the United States Patent and Trademark Office.		‌ Revance Therapeutics, Inc.	United States Patent and Trademark Office	8815954	August 26, 2014
‌ US Patent 10857215 Use of botulinum toxin for the treatment of cerebrovascular disease, renovascular and retinovascular circulatory beds		‌ Revance Therapeutics, Inc.	‌ Revance Therapeutics, Inc.	United States Patent and Trademark Office	10857215	December 8, 2020
‌ US Patent 8974774 Compositions and methods for topical diagnostic and therapeutic transport	Patent 8974774 was granted and assigned to Revance Therapeutics, Inc. on March, 2015 by the United States Patent and Trademark Office.		‌ Revance Therapeutics, Inc.	United States Patent and Trademark Office	8974774	March 10, 2015
‌ US Patent 8092788 Compositions and methods for topical diagnostic and therapeutic transport	Patent 8092788 was granted and assigned to Revance Therapeutics, Inc. on January, 2012 by the United States Patent and Trademark Office.		‌ Revance Therapeutics, Inc.	United States Patent and Trademark Office	8092788	January 10, 2012
‌ US Patent 10441641 Botulinum toxin and the treatment of primary disorders of mood and affect	Patent 10441641 was granted and assigned to Revance Therapeutics, Inc. on October, 2019 by the United States Patent and Trademark Office.	‌ Revance Therapeutics, Inc.	‌ Revance Therapeutics, Inc.	United States Patent and Trademark Office	10441641	October 15, 2019

Results per page:

30 results

0 selected

30 results

0 selected